What is HC Wainwright’s Estimate for VKTX FY2025 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Viking Therapeutics in a report issued on Thursday, October 23rd. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn ($2.73) per share for the year, down from their prior estimate of ($2.48). HC Wainwright has a “Buy” rating and a $102.00 price target on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q4 2025 earnings at ($0.94) EPS.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). During the same quarter in the previous year, the business earned ($0.22) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis.

VKTX has been the subject of several other reports. JPMorgan Chase & Co. lowered their price target on Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a report on Friday. Raymond James Financial lowered their target price on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a research note on Thursday, July 24th. BTIG Research reiterated a “buy” rating and set a $125.00 target price on shares of Viking Therapeutics in a report on Monday, September 22nd. Zacks Research cut Viking Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 21st. Finally, Citigroup lifted their price objective on shares of Viking Therapeutics from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.62.

Viking Therapeutics Trading Up 1.5%

Shares of VKTX stock opened at $34.42 on Monday. The company has a market cap of $3.89 billion, a PE ratio of -16.24 and a beta of 0.64. The company’s fifty day simple moving average is $28.57 and its 200-day simple moving average is $28.83. Viking Therapeutics has a 52 week low of $18.92 and a 52 week high of $81.73.

Institutional Trading of Viking Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VKTX. Avion Wealth raised its holdings in Viking Therapeutics by 1,157.0% in the third quarter. Avion Wealth now owns 1,521 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,400 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Viking Therapeutics by 18,630.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 13,673 shares of the biotechnology company’s stock valued at $359,000 after purchasing an additional 13,600 shares in the last quarter. Ethos Financial Group LLC lifted its position in shares of Viking Therapeutics by 4.0% during the third quarter. Ethos Financial Group LLC now owns 10,969 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 421 shares during the last quarter. SG Americas Securities LLC grew its stake in Viking Therapeutics by 570.7% in the third quarter. SG Americas Securities LLC now owns 95,804 shares of the biotechnology company’s stock worth $2,518,000 after purchasing an additional 81,519 shares in the last quarter. Finally, Global Retirement Partners LLC increased its holdings in Viking Therapeutics by 80.2% in the third quarter. Global Retirement Partners LLC now owns 2,433 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 1,083 shares during the last quarter. Institutional investors own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.